American Association for Cancer Research
15357163mct140422-sup-131673_1_supp_2618995_nckdxl.docx (13.83 kB)

Supplemental Data from Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer

Download (13.83 kB)
journal contribution
posted on 2023-04-03, 14:25 authored by Xinning Wang, Steve S. Huang, Warren D.W. Heston, Hong Guo, Bing-Cheng Wang, James P. Basilion

Supplemental Data. This is the procedures associated with the supplemental data



Prostate cancer is the most common noncutaneous malignancy affecting men in North America. Radical prostatectomy remains a definitive treatment for prostate cancer. However, prostate surgeries are still performed “blindly” with the extent of tumor infiltration past the margins of the surgery only being determined postoperatively. An imaging modality that can be used during surgery is needed to help define the tumor margins. With its abundant expression in prostate cancer, prostate-specific membrane antigen (PSMA) is an ideal target for detection of prostate cancer. The purpose of this study was to develop PSMA-targeted near-infrared (NIR) optical imaging probes for intraoperative visualization of prostate cancer. We synthesized a high-affinity PSMA ligand (PSMA-1) with low molecular weight and further labeled it with commercially available NIR dyes IRDy800 and Cy5.5. PSMA-1 and PSMA-1–NIR conjugates had binding affinities better than the parent ligand Cys-CO-Glu. Selective binding was measured for each of the probes in both in vitro and in vivo studies using competitive binding and uptake studies. Interestingly, the results indicated that the pharmacokinetics of the probes was dependent of the fluorophore conjugated to the PSMA-1 ligand and varied widely. These data suggest that PSMA-targeted probes have the potential to be further developed as contrast agents for clinical intraoperative fluorescence-guided surgery. Mol Cancer Ther; 13(11); 2595–606. ©2014 AACR.